Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. POLEG S., GOLUBCHIK P., OFFEN D., WEIZMAN A. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 8, 89, 90-96. doi: 10.1016/j.pnpbp.2018.08.030 Abstract Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities [...]
Lire la suiteReview article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases Valerio Chiurchiù, Mario van der Stelt, Diego Centonzed, Mauro Maccarrone, Progress in Neurobiology, 2018, 160 , 82–100 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). A B S T R A C T Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a [...]
Lire la suiteTreatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature Nicole Tartaglia, Marcel Bonn-Miller, and Randi Hagerman Cannabis and Cannabinoid Research, 2019, 4, 1 https://doi.org/10.1089/can.2018.0053 Abstract Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and [...]
Lire la suiteLong-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suiteCannabis‐based products for pediatric epilepsy : A systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth K. Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Vijay Shukla, Bláthnaid McCoy, George A. Wells, Epilepsia, 2018, 1-14. DOI: 10.1111/epi.14608 Summary Objective : To assess the benefits and harms of cannabis‐based products for pediatric epilepsy. Methods : We identified in this living systematic review randomized controlled trials (RCTs) and nonrandomized studies (NRSs) involving children with epilepsy treated with cannabis‐based products. We searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature (April 25, 2018). The primary outcome was seizure freedom; secondary outcomes were seizure frequency (total, ≥50% reduction), quality of life, sleep, status epilepticus, death, gastrointestinal adverse [...]
Lire la suiteRapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial ROSS S., BOSSIS A., GUSS J., AGIN-LIEBES G., MALONE T., COHEN B., MENNENGA S.E., BELSER A., KALLIONTZI K., BABB J., SU Z., CORBY P., SCHMIDT B.L. Journal of Psychopharmacology, 2016, 30, 12, 1165-1180 DOI: 10.1177/0269881116675512 jop.sagepub.com Abstract Background : Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods : In this double-blind, placebo-controlled, crossover trial, 29 patients [...]
Lire la suitePsilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : A randomized double-blind trial GRIFFITHS R.R., JOHNSON M.W., CARDUCCI M.A., UMBRICHT A., RICHARDS W.A., RICHARDS B.D., COSIMANO M.P., KLINEDINST M.A. Journal of Psychopharmacology, 2016, 30, 12, 1181–1197. DOI: 10.1177/0269881116675513 jop.sagepub.com Abstract Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose [...]
Lire la suiteQuality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Leor Roseman, David J. Nutt, Robin L. Carhart-Harris Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom Frontiers in Pharmacology, 2018, 8, article 974. Doi : 10.3389/fphar.2017.00974 . Introduction : It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) [...]
Lire la suiteIndividual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy Tara C. Malone, Sarah E. Mennenga, Jeffrey Guss, Samantha K. Podrebarac, Lindsey T. Owens, Anthony P. Bossis, Alexander B. Belser, Gabrielle Agin-Liebes, Michael P. Bogenschutz and Stephen Ross Frontiers in Pharmacology, 2018, 9, 256 doi: 10.3389/fphar.2018.00256 Abstract : A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved quality of life, and serves as a buffer against depression, hopelessness, and desire for hastened death. Historical and recent research suggests a role for psilocybin-assisted psychotherapy in treating cancer-related anxiety and depression. A double-blind controlled trial was performed, where 29 [...]
Lire la suiteCannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats Gracie L. Hay, Sarah J. Baracz, Nicholas A. Everett, Jessica Roberts, Priscila A. Costa, Jonathon C. Arnold, Iain S. McGregor and Jennifer L. Cornish Journal of Psychopharmacology, 2018, 32, (12), 1369-1378. DOI : 10.1177/0269881118799954 , journals.sagepub.com/home/jop Abstract Background : Methamphetamine is an addictive stimulant that can cause many adverse physical, psychological and psychosocial effects. Preliminary evidence shows cannabidiol, a non-intoxicating constituent of the cannabis plant, may have efficacy in treating opioid and nicotine dependence. However, no study has yet examined whether cannabidiol treatment might impact on methamphetamine addiction. Aims : The current study [...]
Lire la suite